# Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

> **NCT03262012** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 416 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** BGF MDI (PT010)
- **DRUG:** GFF MDI (PT003)
- **DRUG:** BFF MDI (PT009)
- **DRUG:** Symbicort® Turbohaler® Inhalation Powder

## Key facts

- **NCT ID:** NCT03262012
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-09
- **Primary completion:** 2018-06-15
- **Final completion:** 2018-06-15
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03262012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03262012, "Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03262012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*